Madison Area Lyme Support Group

Abstract

Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity in preclinical models, including the inhibition of cancer cell proliferation and the targeting of cancer stem cells. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol.

Methods: We analyzed a prospective observational cohort of 197 cancer patients who were prescribed ivermectin and mebendazole off-label through a telemedicine platform by licensed U.S. healthcare providers. Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. As part of a clinical program evaluation, data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) to evaluate self-reported cancer outcomes, medication adherence, and adverse events. 95% confidence intervals (CI) were calculated for primary outcome measures using the Wilson score method. Dose-stratified analyses for outcomes and safety were conducted using Chi-square statistics.

Results: The cohort represented a diverse clinical profile of cancer patients, with mean age of 67 years and nearly balanced sex distribution (52.3% male, 47.7% female). Cancer types included prostate (27.9%), breast (18.3%), lung (8.6%), colon (5.1%), urologic (4.6%), pancreatic (3.0%), liver (2.5%), gynecologic (2.5%), and hematologic (2.5%) malignancies. At enrollment, participants had a median duration since initial diagnosis of 1.2 years, with 37.1% experiencing active disease progression. At 6-month follow-up, medication adherence was high with 86.9% of participants completing the full initial 90-capsule ivermectin-mebendazole prescription and 66.4% remaining on the protocol at 6 months. The Clinical Benefit Ratio (CBR) was 84.4% (95% CI: 77.0–89.8%). Notably, 48.4% (95% CI: 39.7–57.1%) of the cohort reported the strongest positive outcomes, consisting of regression (15.6%; 95% CI: 10.2–23.0%) or no current evidence of disease (NED, 32.8%; 95% CI: 25.1–41.5%). Disease stability was reported to be maintained in 36.1% (95% CI: 28.1–44.9%) of participants, while 15.6% (95% CI: 10.2–23.0%) reported disease progression. While 25.4% reported mild side effects (primarily gastrointestinal), 93.6% of those affected continued treatment through minor dose adjustments. Some participants reported concurrent conventional therapies, including chemotherapy (27.9%), radiation therapy (21.3%), and surgery (19.7%), as well as adjunctive interventions such as supplement use (49.2%), dietary modification (37.7%), and other integrative approaches.

Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumor regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, given the observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials are warranted to validate these observations and further define optimal dosing strategies. (Go to link for full-length study)

_____________

**Comment**

For a wonderful breakdown of the study:  https://justusrhope.substack.com/p/1-in-3-cancer-free-ivermectin-trial?  Excerpt:

Dosages and Concurrent Therapies

Patients were prescribed the medications off-label through a telemedicine platform. They received compounded oral capsules containing:

• 25 mg of Ivermectin
• 250 mg of Mebendazole

The study noted that these were not strictly monotherapies. Many patients were undergoing concurrent conventional treatments, including chemotherapy (27.9%), radiation therapy (21.3%), and surgery (19.7%). Additionally, many used adjunctive interventions such as supplements (49.2%) and dietary modifications (37.7%).

Study Completion and Attrition

Of the initial 197 patients, 75 patients failed to complete the study (meaning they did not complete the 6-month follow-up survey).

• A total of 122 participants completed the 6-month follow-up survey, resulting in a 61.9% response rate.
• Among the 122 who responded, adherence was high: 86.9% completed the full initial 90-capsule prescription, and 66.4% chose to remain on the protocol at the 6-month mark.

Clinical Outcomes and Tolerability

The authors reported an overall Clinical Benefit Ratio (CBR) of 84.4% among the 122 patients who completed the survey. The self-reported outcomes broke down as follows:

• No Evidence of Disease (NED): 32.8%
• Disease Stabilization: 36.1%
• Tumor Regression: 15.6%
• Disease Progression: 15.6%

Within the article, Justuserhope asked AI to evaluate the benefit of adding one agent at a time from the RESET-5 Protocol (Mebendazole, ivermectin, sulforaphane, metformin, and aged garlic extract) to the Hulscher et. al study.  The full RESET-5 reduces the likelihood of resistance development, enhances immune function, and depletes tumors of a critical survival tool – compensatory glutathione production.

The full RESET-5 Protocol boosts improvement even further by 30-40%.

_____________

**Comment**

For those of you studying this, 25 mg of ivermectin and 250mg of Mebendazole are considered pretty low dosages.  Many patients are taking much more than that, so the fact they are getting such great improvement with such low dosages is fairly amazing.  Lower dosages typically mean lower side-effects so this should be safe for nearly all to take.  Share with your doctor and work together to get the best fit.

For more:

• https://madisonarealymesupportgroup.com/2026/04/10/a-new-ivermectin-mebendazole-cocktail-for-cancer-treatment/ Many more links after article.